In a recent webinar, Catalent experts shared their insights on developing intranasal products and scaling them for commercial supply.
This executive summary will share insights into intranasal vaccine formulation development and discuss the current state of the art in intranasal vaccine production from development to commercial scale. In addition, a detailed discussion on the challenges and opportunities of intranasal approaches will be presented including the importance of device selection in determining product performance.
In this executive summary, readers will learn about:
Offered Free by: Catalent Pharma Solutions
See All Resources from: Catalent Pharma Solutions
This download should complete shortly. If the resource doesn't automatically download, please, click here.